| Budget Amount *help |
¥17,680,000 (Direct Cost: ¥13,600,000、Indirect Cost: ¥4,080,000)
Fiscal Year 2019: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2018: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2017: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
|
|---|
| Outline of Final Research Achievements |
Aiming at remedy of multifactorial disease systemic sclerosis, a compound HPH-15 discovered by phenotype screening using cell morphological changes, a prodrug of IP6 that has various physiological activities, and a carnosine derivative that eliminate cytotoxic aldehyde HNE were investigated.
A total of 20 HPH-15 derivatives were synthesized, and 10 of them showed stronger activity than HPH-15 in suppressing collagen production in human skin cells. We also identified the target protein of HPH-15. On the other hand, we demonstrated that the IP6 prodrug Pro-IP6 is cell-permeable and converted into IP6 in the cells. A carnosine derivative CNN showed the HNE capturing activity superior to that of carnosine.
|
